Among women with newly diagnosed breast cancer, a predictive test successfully identified those with a high probability of survival following taxane and anthracycline chemotherapy.
Colorectal tumors with mutations in the MRE11 gene may be vulnerable to PARP inhibitors, a class of drugs that has already demonstrated safety in early clinical trials of breast and ovarian cancers.
A gene mutation may make some patients with squamous cell cancer of the lung more responsive to the drug dasatinib, an existing therapy for chronic myelogenous leukemia.
Two drugs indicated for second- and third-line therapy in persons with advanced non-small-cell lung cancer (NSCLC) appear to be remarkably effective in treating a certain subset of patients.
The presence of high levels of a particular protein in tumors drives metastasis, providing a valuable biomarker for predicting the spread of cancer.
People with a family history of male breast cancer believe they have a higher risk of developing the disease, but are less likely to seek genetic counseling, according to a study published in the journal The American Surgeon. (2010 Aug;76(8):879-882).
Early-stage breast cancer patients can avoid unnecessary chemotherapy by taking a multigene test, according to a study published in the Journal of Clinical Oncology (2010 Jan 11 [Epub ahead of print]).
The first step towards individualised radiotherapy dosing based on a patient’s genetic characteristics and sensitivity to treatment has been taken by an international team of scientists.
